Sex-specific modulation of gut microbiota by empagliflozin contributes to renoprotection in diabetic kidney disease mice
Abstract
Objectives: This study aimed to explore the sex-specific regulatory effects of empagliflozin on gut microbiota in male and female diabetic kidney disease (DKD) mice, and to elucidate the underlying renoprotective mechanisms.
Methods: Four-week-old db/db mice and C57 mice were randomly assigned to six groups. Following 8 weeks of empagliflozin gavage, serum metabolic indices and urinary albumin-to-creatinine ratio (ACR) were measured. Renal pathological alterations were evaluated via hematoxylin-eosin and Masson's trichrome staining. Gut microbiota diversity and community composition were analyzed using 16S rRNA gene sequencing, and Spearman's rank correlation analysis was performed to assess associations between dominant microbial taxa and metabolic/renal parameters.
Results: ACR levels were significantly elevated in db/db mice compared to sex-matched C57 controls, with male db/db mice exhibiting significantly higher ACR than females. Empagliflozin significantly reduced ACR in db/db mice, albeit ACR remained significantly higher in males than females post-treatment. Meanwhile, empagliflozin ameliorated glomerular hypertrophy and mesangial proliferation. Pronounced sexual differences were observed in gut microbiota diversity of db/db mice, with female mice displaying significantly higher microbial richness than males. Empagliflozin effectively reshaped gut microbiota composition and alleviated microbial dysbiosis in db/db mice, with these regulatory effects showing distinct…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.